University of Minnesota Medical School finds promising treatment to slow kidney disease doesn't prove out in clinical trial

June 25, 2020

MINNEAPOLIS, MN- June 25, 2020 - Historically, half or more of people with type 1 diabetes develop kidney disease, which frequently progresses to kidney failure, requiring dialysis treatment or kidney transplantation for survival, according to a study in Diabetes Care. Development and progression of kidney disease in type 1 diabetes is associated with higher levels of a chemical in the blood called uric acid. A new study from the University of Minnesota Medical School found that allopurinol, an inexpensive generic drug that reduces uric acid levels, did not show benefits in protecting from loss of filtering function in the kidney. The findings were recently published in the New England Journal of Medicine

Previous studies suggested that allopurinol may be a promising treatment to slow kidney function, but the smaller size of the studies indicated the need for a more definitive, large-scale trial to answer this important question. 

Michael Mauer, MD, professor in the Departments of Pediatrics and Medicine and kidney specialist at the University of Minnesota Medical School, and his colleagues conducted an international, multi-institution, randomized clinical trial that enrolled 530 participants to study whether allopurinol would slow the disease. The study participants had type 1 diabetes and early to moderate loss of the kidney's filtering function.

Mauer is the co-principal investigator of the study called, Preventing Early Renal Loss in Diabetes (PERL), along with his colleague, Alessandro Doria, MD, PhD, MPH, senior investigator in Joslin Diabetes Center's Section on Genetics and Epidemiology and professor of Medicine at Harvard Medical School. Mauer has conducted studies of diabetic kidney disease for more than 40 years and has published extensively in this field.

The PERL consortium consisted of 16 sites each led by excellent clinical scientists. Participants in the three-year, placebo-controlled and double-blinded trial received the current standard of care, including a renin-angiotensin system inhibitor--an existing type of drug shown in the 1990s to slow kidney damage, albeit incompletely. 

The key outcome measurement of kidney function for PERL was glomerular filtration rate (GFR), a measure of how much blood is filtered every minute by the kidneys. GFR drops as kidney disease progresses, and when very low, requires dialysis or kidney transplantation for survival. Over the three years of the study, levels of uric acid was decreased, on average, by about 35% among people given allopurinol compared to those who were not. Despite the reduction in uric acid levels, the study showed there was no effect on GFR.

"PERL was a textbook example of using basic science, epidemiology findings and preliminary pilot studies to identify a treatment target, and then to design a study to answer an important question," Mauer said. "In this case, we didn't get the result we were hoping for, but we got a clear answer to an important scientific question."

This research was supported  by the National Institute of Diabetes and Digestive and Kidney Diseases and the Juvenile Diabetes Research Fund. 

University of Minnesota co-investigators included Luiza Maria Caramori, MD, PhD, the U of M PERL site director; William Robiner, PhD, the PERL study psychologist, and Amy Karger, MD, PhD, the PERL laboratory director. 

Other co-investigators included Andrzej Galecki, Cathie Spino, Chunyi Wu and Rodica Pop-Busi, University of Michigan; Allison Goldfine and Sylvia Rosas, Joslin Clinic; David Cherney and Bruce Perkins, University of Toronto; Ildiko Lingvay, University of Texas Southwestern Medical School; Afshin Parsa, NIH; Peter Rossing, University of Copenhagen; Ronald Sigal, University of Calgary; Maryam Afkarian, University of California at Davis; Ronnie Aronson of LMC Diabetes & Endocrinology, Toronto; Jill Crandall, Albert Einstein College of Medicine; Ian de Boer and Irl Hirsch, University of Washington; Katherine Tuttle, University of Washington; Thomas Elliott of BCDiabetes, Vancouver; Jeehea Haw and Guillermo Umpierrez, Emory University; David Maahs and Sarit Polsky, University of Colorado; Janet McGill, Washington University; Mark Molitch and Amisha Wallia, Northwestern University; Marlon Pragnell, JDRF; Peter Senior, University of Alberta; and Ruth Weinstock, SUNY Upstate Medical University.
About the University of Minnesota Medical School

The University of Minnesota Medical School is at the forefront of learning and discovery, transforming medical care and educating the next generation of physicians. Our graduates and faculty produce high-impact biomedical research and advance the practice of medicine. Visit to learn how the University of Minnesota is innovating all aspects of medicine.

Kelly Glynn
Media Relations Coordinator, University of Minnesota Medical School

University of Minnesota Medical School

Related Diabetes Articles from Brightsurf:

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to